Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1143 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.5172 0.10782
HCC1143 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.3577 0.17008
HCC1143 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 0.3575 0.18898
HCC1143 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 0.3277 0.16693
HCC1143 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 0.2573 0.17426
HCC1143 Trametinib
0.0001
MEK
MAPK/nRTK
 0.9383 -0.00019
HCC1143 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.8814 0.00247
HCC1143 Trametinib
0.001
MEK
MAPK/nRTK
 0.7968 0.01121
HCC1143 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.6210 0.03758
HCC1143 Trametinib
0.01
MEK
MAPK/nRTK
 0.5178 0.06411
HCC1143 Trametinib
0.031623
MEK
MAPK/nRTK
 0.2891 0.10454
HCC1143 Trametinib
0.1
MEK
MAPK/nRTK
 0.1417 0.18104
HCC1143 Trametinib
0.31623
MEK
MAPK/nRTK
 -0.0092 0.28061
HCC1143 Trametinib
1.0
MEK
MAPK/nRTK
 -0.0225 0.38659
HCC1143 Saracatinib
0.001
SRC
MAPK/nRTK
 1.0018 0.00380
HCC1143 Saracatinib
0.0031623
SRC
MAPK/nRTK
 0.9768 0.00743
HCC1143 Saracatinib
0.01
SRC
MAPK/nRTK
 0.9608 0.01503
HCC1143 Saracatinib
0.031623
SRC
MAPK/nRTK
 0.8235 0.02422
HCC1143 Saracatinib
0.1
SRC
MAPK/nRTK
 0.7787 0.02844
HCC1143 Saracatinib
0.31623
SRC
MAPK/nRTK
 0.7539 0.03392
HCC1143 Saracatinib
1.0
SRC
MAPK/nRTK
 0.6295 0.06233
HCC1143 Saracatinib
3.1623
SRC
MAPK/nRTK
 0.4818 0.10250
HCC1143 Saracatinib
10.0
SRC
MAPK/nRTK
 0.3881 0.11527
HCC1143 ABT-737
0.001
Bcl2/XL
Misc
 1.0058 -0.00733
HCC1143 ABT-737
0.0031623
Bcl2/XL
Misc
 1.0543 -0.00609